Charles river and aitia enter strategic agreement to utilize logica in discovery programs for neurodegenerative diseases and oncology

Strategic partnership includes co-development of patient-derived xenograft (pdx) digital twins for in vivo oncology research charles river to make an equity investment in aitia as part of the agreement wilmington, mass. and somerville, mass.
CRL Ratings Summary
CRL Quant Ranking